Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity

BACKGROUND: Cancer immunotherapy has taken center stage in cancer treatment. However, the current immunotherapies only benefit a small proportion of patients with cancer, necessitating better understanding of the mechanisms of tumor immune evasion and improved cancer immunotherapy strategies. Regula...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalim, Khalid W, Yang, Jun-Qi, Wunderlich, Mark, Modur, Vishnu, Nguyen, Phuong, Li, Yuan, Wen, Ting, Davis, Ashley Kuenzi, Verma, Ravinder, Lu, Qing Richard, Jegga, Anil G, Zheng, Yi, Guo, Fukun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703354/
https://www.ncbi.nlm.nih.gov/pubmed/36427906
http://dx.doi.org/10.1136/jitc-2022-004806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703354/
https://www.ncbi.nlm.nih.gov/pubmed/36427906
http://dx.doi.org/10.1136/jitc-2022-004806

Ejemplares similares